Phase 1 Schizophrenia Trial, Recruiting NCT06105151 Sponsor: Vigonvita Life Sciences Condition: Schizophrenia
Back to Schizophrenia

Phase 1 Schizophrenia Trial, Recruiting

NCT06105151
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men aged 18 to 45 years old who weigh at least 50 kg, or women aged 18 to 60 years old who weigh at least 45 kg, with a body mass index (a height-to-weight ratio) between 19.0 and 26.0
  • People whose general health check-ups, including physical examination, vital signs, blood tests, and heart tracing (ECG), come back normal or with no medically significant findings
  • Male participants who are willing to use effective contraception during the study and for 3 months after it ends; female participants who are not able to become pregnant
  • People who are able to understand and follow the study instructions and who have freely chosen to take part by signing a consent form

Who may not be able to join:

  • People who have a current or past history of significant illness or organ dysfunction affecting the nervous system, heart, lungs, digestive system, kidneys, hormones, blood, eyes, or other areas, or who have a history of cancer or other conditions the trial doctors consider unsuitable
  • People with a current or past history of mental health disorders, brain dysfunction, self-harm, or who are assessed by the trial doctor as being at risk of suicide
  • People who have had surgery on their digestive system (such as stomach removal or bowel resection) or who have conditions that may significantly affect how the body processes a drug, or who have a history of urinary blockage, gastrointestinal ulcers, or gastrointestinal bleeding
  • People with a known allergy to the ingredients in the trial drug or similar medicines, or who have a history of allergic conditions
  • People who test positive for hepatitis B, hepatitis C, syphilis, or HIV
  • People who have had surgery within the 3 months before screening, have not yet fully recovered from surgery, or have a planned surgery scheduled during the trial period
  • People who have donated or lost 400 mL or more of blood in the 3 months before screening, or 200 mL or more in the month before screening, or who have received blood products in the 3 months before screening
  • People who have taken any prescription medicines, over-the-counter medicines, vitamins, or herbal products in the 2 weeks before screening
  • People who have used medicines that affect how the liver breaks down certain drugs (specific enzyme inducers or inhibitors) within 4 weeks — or 5 half-lives of the drug, whichever is longer — before screening
  • People who have taken part in another clinical trial or received a trial drug within the 3 months before screening, or who are currently enrolled in another clinical trial
  • People who tested positive on a smoke test, smoke more than 5 cigarettes per day, drink more than 5 cups of coffee or tea per day, or who are unable to stop these during the study — assessed over the 3 months before screening
  • People who have had a pattern of heavy alcohol use in the year before screening, averaging more than 14 standard drinks per week, or who test positive on a breath alcohol test
  • People with a history of drug misuse in the year before screening, or who test positive on a urine drug screen
  • People who have a family history of sudden cardiac death in a relative who died suddenly before the age of 40
  • People whose resting heart rate, blood pressure readings, or drop in blood pressure upon standing fall outside the acceptable ranges set by the trial (confirm with trial site for exact values)
  • People whose heart tracing (ECG) shows abnormalities that the trial doctor considers clinically significant, including certain measurements of heart rhythm that exceed defined limits
  • People whose blood test results for liver enzymes, kidney function markers, or prolactin levels are above the normal upper limit
  • People who have special dietary requirements, difficulty swallowing, or who are unable to follow a standard diet during the trial
  • People who are unwilling to avoid smoking, alcohol, caffeine-containing drinks, and intense exercise during the trial
  • People who are directly involved in running this clinical trial
  • People whom the trial doctors consider unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Gang Wang, Beijing Anding Hospital of Capital Medical University

Phone: +8618061926005

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Vigonvita Life Sciences
Registry
ClinicalTrials.gov
Start date
27 October 2023
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Treatment-Emergent Adverse Events; Incidence of Treatment-Emergent Adverse Events; Cmax; Cmax; area under the plasma concentration time curve from time zero to the last(AUC0-t); area under the plasma concentration time curve from time zero to the last(AUC0-t); AUC0-∞; AUC0-∞; Tmax; Tmax; t1/2; t1/2; Apparent Clearance Rate(CL/F); Apparent Clearance Rate(CL/F); Vd/F; Vd/F; Ke; Ke; mean Resident Time from time zero to the last(MRT0-t); mean Resident Time from time zero to the last(MRT0-t); mean Resident Time from time zero to infinity(MRT0-∞); mean Resident Time from time zero to in...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov